Clinical Trials Logo

Clinical Trial Summary

Leflunomide versus Azathioprine for Maintenance Therapy of Lupus Nephritis


Clinical Trial Description

Proliferative glomerulonephritis is a common and severe manifestation of systemic lupus erythematosus (SLE) that usually requires intensive therapy with high doses of glucocorticosteroids and cytotoxic drugs, such as intravenous (IV) cyclophosphamide (CYC). The objective of this Trial is to compare leflunomide (LEF) and azathioprine (AZA), in terms of efficacy and toxicity, as remission-maintaining treatment of proliferative lupus glomerulonephritis, after a remission-inducing therapy with a short-course IV CYC regimen. The hypothesis of this trial is that LEF is non-inferior to AZA. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01172002
Study type Interventional
Source RenJi Hospital
Contact Bao Chun De
Phone 086-02158752345
Email baochunde_1678@yahoo.com.cn
Status Recruiting
Phase N/A
Start date March 2010

See also
  Status Clinical Trial Phase
Recruiting NCT06013995 - A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus Phase 1
Recruiting NCT03952624 - Patient-Centered Assessment of Symptoms and Outcomes
Terminated NCT01389895 - Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Phase 1
Completed NCT00710021 - Vitamin D3 in Systemic Lupus Erythematosus Phase 2
Completed NCT02265744 - Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Phase 2
Completed NCT00581763 - Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies N/A
Completed NCT00299819 - Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT00054938 - Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) Phase 2
Terminated NCT03953690 - Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France
Recruiting NCT05715463 - Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity N/A
Enrolling by invitation NCT05321108 - Aerobic Exercise Versus Whole-Body Vibration on Fatigue, Functional Capacity, Quality of Life in Systemic Lupus N/A
Completed NCT00482989 - A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus Phase 1
Completed NCT00657189 - A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Phase 2
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Completed NCT03402087 - A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients Phase 1
Completed NCT02857452 - Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire N/A
Terminated NCT03186794 - Aerobic Exercise in Women With Systemic Lupus Erythematosus N/A
Recruiting NCT05922722 - Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus
Completed NCT03093402 - JBT-101 in Systemic Lupus Erythematosus (SLE) Phase 2
Recruiting NCT05018858 - Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus Phase 1